文献速递主动脉疾病

开窗与分支腔内移植物用于主动脉弓部分及全腔内修复的结局——系统评价与荟萃分析

Outcomes of Fenestrated and Branched Endografts for Partial and Total Endovascular Repair of the Aortic Arch - A Systematic Review and Meta-Analysis.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2023-08-02

该系统评价与荟萃分析检索2018至2021年文献,纳入18项研究共571例以开窗或分支胸主动脉腔内修复(F/B-TEVAR)治疗主动脉弓病变的患者。汇总技术成功率为95.9%(95%CI 0.93-0.97;I²=0%;异质性P=.77),30天死亡率为6.7%(95%CI 0.05-0.09;I²=0%;异质性P=.66)。开窗与分支移植物比较除F-TEVAR的I-III型内漏发生率更高(9.8% vs 2.6%;P=.034)外无统计学差异。

要点

  • F/B-TEVAR治疗主动脉弓病变汇总技术成功率95.9%,30天死亡率6.7%。
  • 开窗与分支移植物比较,仅F-TEVAR的I-III型内漏发生率更高(9.8% vs 2.6%;P=.034)。
  • 1年随访总生存率与免于主动脉相关死亡分别为82-96.4%和94-94.7%。

核心结论

  • 在专门中心经验下,F/B-TEVAR治疗主动脉弓病变的技术成功率达到满意水平,早期死亡率逐步降低;但存在若干局限性,需进一步研究以得出更明确结论。

研究设计与样本

  • 系统评价与荟萃分析,按PRISMA指南实施;检索PubMed、Scopus和Cochrane Library(2018-2021年)。
  • 筛选458篇文章后纳入18项研究,共571例患者;纳入择期、紧急或急诊需近端锚定区位于主动脉弓(0-1-2区)并接受F/B-TEVAR的患者。
  • 排除开放修复、主动脉上干(SAT)去分支联合标准TEVAR、原位医师改良移植物及平行移植物。

主要发现

  • 干预指征为慢性夹层(50.1%)、退行性动脉瘤(39.6%)、穿透性主动脉溃疡(7.4%)和假性动脉瘤(2%)。
  • F-TEVAR、B-TEVAR和F+B-TEVAR分别用于38.4%、54.1%和7.5%的患者。
  • 总体技术成功率为95.9%(95%CI 0.93-0.97;I²=0%;异质性P=.77),30天死亡率为6.7%(95%CI 0.05-0.09;I²=0%;异质性P=.66)。
  • 开窗与分支移植物比较无统计学差异,唯F-TEVAR的I-III型内漏发生率更高(9.8% vs 2.6%;P=.034)。
  • 1年随访总生存率和免于主动脉相关死亡分别介于82-96.4%和94-94.7%。

关键数值与推荐

  • 技术成功定义为95.9%(95%CI 0.93-0.97;I²=0%;异质性P=.77)。
  • 30天死亡率为6.7%(95%CI 0.05-0.09;I²=0%;异质性P=.66)。
  • F-TEVAR的I-III型内漏发生率为9.8%,B-TEVAR为2.6%(P=.034)。
  • 1年总生存率介于82-96.4%,免于主动脉相关死亡介于94-94.7%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 13项研究被评为中等偏倚风险,5项研究被评为高偏倚风险。
  • 存在若干局限性,需进一步研究以得出更明确结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Fenestrated and branched thoracic endovascular aortic repair (F/B-TEVAR) of the aortic arch is a viable approach in patients unsuitable for open repair. The aim was to summarise the published results of manufactured F/B-TEVAR devices for partial and total repair of the aortic arch, and to compare fenestrated with branched configurations. DATA SOURCES: PubMed, Scopus and The Cochrane Library were searched for articles (2018 - 2021) about patients with elective, urgent, or emergency aortic requiring a proximal landing zone in the aortic arch (zone 0 - 1 - 2) and treated by F/B-TEVAR. REVIEW METHODS: The systematic review and meta-analysis were performed according to the PRISMA guidelines. Open repair, supra-aortic trunk (SAT) debranching + standard TEVAR, and in situ physician modified and parallel grafts were excluded. Primary outcomes were technical success and 30 day mortality rate. Secondary outcomes were 30 day major adverse events, and overall survival and procedure related endpoints during follow up. RESULTS: Of 458 articles screened, 18 articles involving 571 patients were selected. Indications for intervention were chronic dissections (50.1%), degenerative aneurysms (39.6%), penetrating aortic ulcers (7.4%), and pseudoaneurysms (2%). F-TEVAR, B-TEVAR, and F+B-TEVAR were used in 38.4%, 54.1%, and 7.5% of patients, respectively. Overall, technical success was 95.9% (95% confidence interval [CI] 0.93 - 0.97; I2 = 0%; p for heterogeneity (Het) = .77) and the 30 day mortality rate was 6.7% (95% CI 0.05 - 0.09; I2 = 0%; p Het = .66). No statistical differences were found comparing fenestrated with branched endografts, except for a higher rate of type I - III endoleaks in F-TEVAR (9.8% vs. 2.6%; p = .034). The overall survival rate and freedom from aortic related death at the one year follow up ranged between 82 - 96.4% and 94 - 94.7%, respectively. Thirteen and five studies were considered at moderate and high risk of bias, respectively. CONCLUSION: F/B-TEVAR for the treatment of the aortic arch, according to experience in dedicated centres, now enjoys a satisfactory level of technical success together with a progressively reduced early mortality rate. There are several limitations, and further studies are needed to reach clearer conclusions.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Spath P, Campana F, Tsilimparis N, et al. Outcomes of Fenestrated and Branched Endografts for Partial and Total Endovascular Repair of the Aortic Arch - A Systematic Review and Meta-Analysis. Eur J Vasc Endovasc Surg. 2023. PMID: 37536517. doi:10.1016/j.ejvs.2023.07.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。